News about Market

Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands

Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

Market | 15/12/2025 | By News Bureau |  345

Senores Pharma Wins US FDA Approval for Deferiprone Tablets, Launched by Dr Reddy's

Senores Pharmaceuticals has announced the approval and US launch of Deferiprone Tablets USP (500 mg and 1000 mg), to be marketed by Dr Reddy’s Laboratories Inc.

Market | 15/12/2025 | By News Bureau |  414

Gaelic Laboratories Strengthens Manufacturing Footprint with Acquisition of Athlone Laboratories

Gaelic Laboratories, an Ireland-based manufacturer of beta-lactam (penicillin) products established in 2022, has acquired Athlone Laboratories, a long-standing developer and manufacturer of oral-dose beta-lactam medicines.

Market | 14/12/2025 | By Darshana |  212

Orphalan announces acquisition of Orphelia Pharma

Orphalan has strengthened its leadership in rare diseases with the acquisition of Orphelia Pharma, expanding its global footprint and enhancing its portfolio of treatments for severe paediatric neurological and oncological conditions.

Market | 12/12/2025 | By Akanki |  350

Platform Technologies Drive USD 211 Billion Surge in Precision Cancer Treatment

The rapid rise of platform technologies has added USD 211 billion in value to the precision oncology landscape, with immunotherapies now accounting for more than 45 percent of global anticancer drug revenues—underscoring strong investor confidence in biologically targeted treatment approaches.

Market | 12/12/2025 | By Akanki |  262

US FDA Approves Uplizna for Adults with Generalised Myasthenia Gravis

The US FDA has approved Uplizna for adults with generalised myasthenia gravis, marking a significant advancement as the first and only CD19-targeted B-cell therapy for both anti-AChR and anti-MuSK antibody–positive patients, offering durable disease control with just twice-yearly dosing.

Market | 12/12/2025 | By Akanki |  203

Cycle Pharmaceuticals to Acquire Applied Therapeutics

The acquisition positions Cycle Pharmaceuticals to strengthen its rare disease portfolio, adding Applied Therapeutics’ promising CNS-penetrant aldose reductase inhibitor, govorestat, which targets severe unmet needs in central nervous system metabolic disorders.

Market | 12/12/2025 | By Akanki |  272

D3 Bio Secures USD 108 Million in Series B Financing to Advance Global Clinical Programmes

D3 Bio has raised USD 108 million in Series B financing to advance its global clinical programmes. The funds will support the Phase III pivotal trial of its lead asset, elisrasib (D3S-001), while also accelerating the development of the company’s broader pipeline of targeted and immuno-oncology therapies with first-in-class and best-in-class potential.

Market | 11/12/2025 | By Akanki |  380

Novo Nordisk Completes Acquisition of Akero Therapeutics

Novo Nordisk has finalised its acquisition of Akero Therapeutics, making Akero a wholly owned subsidiary. Following the transaction, Akero’s common stock will cease trading on the Nasdaq Global Select Market.

Market | 10/12/2025 | By Akanki |  314

Terns Prices Upsized USD 650 Million Public Offering

Terns plans to use the proceeds to advance research and clinical development of its pipeline, including TERN-701, support early commercial launch preparations, and fund working capital and general corporate needs.

Market | 10/12/2025 | By Akanki |  267